Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Key Insights

• The projected fair value for Halozyme Therapeutics is US$57.30 based on 2 Stage Free Cash Flow to Equity
• Halozyme Therapeutics is estimated to be 38% undervalued based on current share price of US$35.70
• Our fair value estimate is 8.7% higher than Halozyme Therapeutics' analyst price target of US$52.70

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Halozyme Therapeutics, Inc. (NASDAQ:HALO) as an investment opportunity by projecting its future cash flows and then discounting them to today's value. We will use the Discounted Cash Flow (DCF) model on this occasion. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.

Check out our latest analysis for Halozyme Therapeutics

Is Halozyme Therapeutics Fairly Valued?

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) estimate

	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032
Levered FCF ($, Millions)	US$314.5m	US$486.0m	US$472.0m	US$466.0m	US$464.8m	US$466.8m	US$471.2m	US$477.2m	US$484.4m	US$492.5m
Growth Rate Estimate Source	Analyst x2	Analyst x2	Analyst x1	Est @ -1.26%	Est @ -0.26%	Est @ 0.44%	Est @ 0.93%	Est @ 1.27%	Est @ 1.51%	Est @ 1.68%
Present Value ($, Millions) Discounted @ 7.4%	US$293	US$421	US$381	US$350	US$325	US$304	US$286	US$270	US$255	US$241

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$3.1b

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.1%. We discount the terminal cash flows to today's value at a cost of equity of 7.4%.

Terminal Value (TV)= FCF₂₀₃₂ × (1 + g) ÷ (r – g) = US$492m× (1 + 2.1%) ÷ (7.4%– 2.1%) = US$9.4b

Present Value of Terminal Value (PVTV)= TV / (1 + r)¹⁰= US$9.4b÷ ( 1 + 7.4%)¹⁰= US$4.6b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$7.8b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of US$35.7, the company appears quite good value at a 38% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

The Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Halozyme Therapeutics as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 0.896. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Halozyme Therapeutics

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a discount to intrinsic value? For Halozyme Therapeutics, there are three fundamental elements you should assess:

1. Risks: For instance, we've identified 3 warning signs for Halozyme Therapeutics (1 is significant) you should be aware of.
2. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for HALO's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.
3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.